Lv6
2310 积分 2021-07-06 加入
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance
17天前
已完结
Actions of thyroid hormones and thyromimetics on the liver
17天前
已完结
Pharmacological treatment for metabolic dysfunction–associated steatotic liver disease and related disorders: Current and emerging therapeutic options
17天前
已完结
Insights into the results of Resmetirom trials: Can a thyroid hormone receptor agonist be the holy grail of MASH therapy?
17天前
已完结
Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance
17天前
已完结
Therapeutic horizons in metabolic dysfunction–associated steatohepatitis
17天前
已完结
Mechanisms and therapeutic insights into MASH-associated fibrosis
17天前
已完结
Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis
2个月前
已完结
Therapeutic horizons in metabolic dysfunction–associated steatohepatitis
2个月前
已完结
皖公网安备34019202002308
